Inter J Stomatol ›› 2017, Vol. 44 ›› Issue (1): 83-86.doi: 10.7518/gjkq.2017.01.017
• ·Reviews· • Previous Articles Next Articles
Li Xiao, Ji Tong.
CLC Number:
[1] 郭伟. 头颈肿瘤诊断治疗学[M]. 北京: 人民军医出版社, 2013:196-207. Guo W. Diagnosis and treatment of head and neck cancer[M]. Beijing: People’s Military Medical Press, 2013:196-207. [2] Taghavi N, Mehrdad L, Rajabi M, et al. A 10-year retrospective study on malignant jaw tumors in Iran [J]. J Craniofac Surg, 2010, 21(6):1816-1819. [3] van den Berg H, Merks JH. Incidence and grading of cranio-facial osteosarcomas[J]. Int J Oral Maxillofac Surg, 2014, 43(1):7-12. [4] Wang S, Shi H, Yu Q. Osteosarcoma of the jaws: demographic and CT imaging features[J]. Dentoma-xillofac Radiol, 2012, 41(1):37-42. [5] Kämmerer PW, Shabazfar N, Vorkhshori Makoie N, et al. Clinical, therapeutic and prognostic features of osteosarcoma of the jaws-experience of 36 cases[J]. J Craniomaxillofac Surg, 2012, 40(6):541-548. [6] Argon A, Doğanavşargıl B, Ünal Yıldırım F, et al. Osteosarcomas of jaw: experience of a single centre [J]. J Plast Surg Hand Surg, 2015, 49(1):13-18. [7] Mücke T, Mitchell DA, Tannapfel A, et al. Effect of neoadjuvant treatment in the management of osteo-sarcomas of the head and neck[J]. J Cancer Res Clin Oncol, 2014, 140(1):127-131. [8] Miwa S, Takeuchi A, Shirai T, et al. Prognostic value of radiological response to chemotherapy in patients with osteosarcoma[J]. PLoS One, 2013, 8(7):e70015. [9] Sakamoto A, Iwamoto Y. Current status and perspec-tives regarding the treatment of osteosarcoma: chemotherapy[J]. Rev Recent Clin Trials, 2008, 3(3): 228-231. [10] Gill J, Ahluwalia MK, Geller D, et al. New targets and approaches in osteosarcoma[J]. Pharmacol Ther, 2013, 137(1):89-99. [11] Meyers PA, Schwartz CL, Krailo MD, et al. Osteo-sarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival—a report from the Children’s Oncology Group[J]. J Clin Oncol, 2008, 26(4):633-638. [12] Chou AJ, Kleinerman ES, Krailo MD, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children’s Oncology Group[J]. Cancer, 2009, 115(22):5339-5348. [13] Smith MA, Seibel NL, Altekruse SF, et al. Outcomes for children and adolescents with cancer: challenges for the twenty-first century[J]. J Clin Oncol, 2010, 28(15):2625-2634. [14] Anninga JK, Gelderblom H, Fiocco M, et al. Chemo-therapeutic adjuvant treatment for osteosarcoma: where do we stand[J]. Eur J Cancer, 2011, 47(16): 2431-2445. [15] Daw NC, Neel MD, Rao BN, et al. Frontline treat-ment of localized osteosarcoma without methotrexate [J]. Cancer, 2011, 117(12):2770-2778. [16] 邱蔚六, 郑家伟. 应重视口腔颌面部恶性肿瘤的综合序列治疗[J]. 中国口腔颌面外科杂志, 2005, 3 (3):179-182. Qiu WL, Zheng JW. Comprehensive and sequential therapy for oral and maxillofacial malignancies: an evolving concept and clinical significance[J]. Chin J Oral Maxillofac Surg, 2005, 3(3):179-182. [17] Granowski-LeCornu M, Chuang SK, Kaban LB, et al. Osteosarcoma of the jaws: factors influencing prognosis[J]. J Oral Maxillofac Surg, 2011, 69(9): 2368-2375. [18] Thariat J, Julieron M, Brouchet A, et al. Osteosar-comas of the mandible: are they different from other tumor sites[J]. Crit Rev Oncol Hematol, 2012, 82(3): 280-295. [19] Thariat J, Schouman T, Brouchet A, et al. Osteosar-comas of the mandible: multidisciplinary manage-ment of a rare tumor of the young adult a cooperative study of the GSF-GETO, Rare Cancer Network, GETTEC/REFCOR and SFCE[J]. Ann Oncol, 2013, 24(3):824-831. [20] Mali B, Jarm T, Snoj M, et al. Antitumor effective-ness of electrochemotherapy: a systematic review and meta-analysis[J]. Eur J Surg Oncol, 2013, 39(1): 4-16. [21] Campana LG, Bertino G, Rossi CR, et al. The value of electrochemotherapy in the treatment of peristomal tumors[J]. Eur J Surg Oncol, 2014, 40(3):260-262. [22] Isobe K, Shimizu T, Nikaido T, et al. Low-voltage electrochemotherapy with low-dose methotrexate enhances survival in mice with osteosarcoma[J]. Clin Orthop Relat Res, 2004(426):226-231. [23] Mücke T, Mitchell DA, Tannapfel A, et al. Outcome in adult patients with head and neck sarcomas—a 10-year analysis[J]. J Surg Oncol, 2010, 102(2):170- 174. [24] Mendenhall WM, Fernandes R, Werning JW, et al. Head and neck osteosarcoma[J]. Am J Otolaryngol, 2011, 32(6):597-600. [25] 李江, 何荣根. 颌面部骨肉瘤61例临床病理研究[J]. 中华口腔医学杂志, 2003, 38(6):444-446. Li J, He RG. Osteosarcoma of maxillofacial area: a clinicopathological study of 61 cases[J]. Chin J Stomatol , 2003, 38(6):444-446. [26] Smith RB, Apostolakis LW, Karnell LH, et al. Na-tional Cancer Data Base report on osteosarcoma of the head and neck[J]. Cancer, 2003, 98(8):1670- 1680. [27] Whelan J, McTiernan A, Cooper N, et al. Incidence and survival of malignant bone sarcomas in England 1979—2007[J]. Int J Cancer, 2012, 131(4):E508- E517. [28] Junior AT, de Abreu Alves F, Pinto CA, et al. Clini-copathological and immunohistochemical analysis of twenty-five head and neck osteosarcomas[J]. Oral Oncol, 2003, 39(5):521-530. [29] Eid A, Li S, Garza R, et al. Chemotherapy for oral and maxillofacial tumors: an update[J]. Oral Maxi-llofac Surg Clin North Am, 2014, 26(2):163-169. [30] Luetke A, Meyers PA, Lewis I, et al. Osteosarcoma treatment-where do we stand? A state of the art review[J]. Cancer Treat Rev, 2014, 40(4):523-532. [31] Kuba K, Inoue H, Hayashi T, et al. Laryngeal osteo-sarcoma: case report and literature review[J]. Head Neck, 2015, 37(2):E26-E29. [32] Beckingsale TB, Gerrand CH. Osteosarcoma[J]. Orthopaed Trauma, 2010, 24(5):321-331. [33] Park HR, Cabrini RL, Araujo ES, et al. Expression of ezrin and metastatic tumor antigen in osteo-sarcomas of the jaw[J]. Tumori, 2009, 95(1):81-86. (本文采编 王晴) |